Search companies

Live

Tuesday, 17 November 2026 · 558 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Clarity Pharmaceuticals Reports $153 Million Cash Balance as Prostate Cancer Trials Advance

CU6: $1.57 -5.99% · MC: $619M

Clarity Pharmaceuticals ended September with approximately $153 million in cash. Its SECuRE treatment trial reached its main expansion-group recruitment target in October, while recruitment continues for a group receiving the treatment alongside enzalutamide. Earlier this week, Clarity reported that its Phase III CLARIFY imaging trial had dosed its target number of participants; results from that trial and AMPLIFY are expected in the first half of next year.

Source announcements: 2026-10-30 15:40 to 2026-10-30 15:40 Sydney time
Story updated 2026-10-30 15:45 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments